Alphabet’s life sciences company Verily has signed an agreement to form a new US-based joint venture (JV) with health devices maker ResMed to help patients with sleep apnoea.

The JV will integrate ResMed’s sleep apnoea expertise and Verily’s health data analytics technologies to investigate the impacts of undiagnosed and untreated form of this condition on health and financial aspects.

In addition, the JV will work on development of software solutions to aid healthcare providers in efficient identification, diagnosis, treatment and management of people suffering from breathing-related sleep disorders, including sleep apnoea.

ResMed chief medical officer Carlos Nunez said: “The vast majority of people with sleep apnoea don’t realise they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks.

“Med and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health and quality of life.”

“The combined industry expertise, scalable infrastructure, and data analytics capabilities of ResMed and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health and quality of life.”

Subject to customary closing conditions and regulatory approvals, the JV will operate as a stand-alone entity from the companies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Verily chief medical and scientific officer Jessica Mega said: “Approaching a widespread health problem like sleep apnoea through collecting, organising and activating health data is central to Verily’s mission.

“By better identifying at-risk individuals as well as generating real-world evidence regarding the value and effectiveness of treatment, this collaboration has the potential to improve outcomes for millions of people living with sleep apnoea, and potentially other related conditions.”

Sleep apnoea is estimated to affect 54 million people in the US and can lead to heart disease, stroke, type 2 diabetes and other life-threatening conditions. Research showed the condition to be undiagnosed and untreated in 80% of the patients.